The role of protein kinase C-alpha (PKC-α) in cancer and its modulation by the novel PKC-α-specific inhibitor aprinocarsen : Signal transduction therapy: Facts and visionsHANAUSKE, A.-R; SUNDELL, Karen; LAHN, Michael et al.Current pharmaceutical design. 2004, Vol 10, Num 16, pp 1923-1936, issn 1381-6128, 14 p.Article

Recent improvements in the human tumor cloning assay for sensitivity testing of antineoplastic agentsHANAUSKE, A.-R; HANAUSKE, U; VON HOFF, D. D et al.European journal of cancer & clinical oncology. 1987, Vol 23, Num 6, pp 603-605, issn 0277-5379Article

Evidence for binding of extrachromosomal DNA sequences to nuclear matrix proteins in multidrug-resistant KB-V1 cellsTHIEBAUT, F; HANAUSKE, A.-R; VON HOFF, D. D et al.FEBS letters. 1993, Vol 319, Num 1-2, pp 133-137, issn 0014-5793Article

Recombinant human transforming growth factor-alpha stimulates in vitro colony formation of fresh human tumor specimensHANAUSKE, A.-R; HANAUSKE, U; BUCHOK, J et al.International journal of cell cloning. 1988, Vol 6, Num 3, pp 221-229, issn 0737-1454Article

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitroDEPENBROCK, H; SHIRVANI, A; RASTETTER, J et al.Investigational new drugs. 1995, Vol 13, Num 3, pp 187-193, issn 0167-6997Article

Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patientsSCHILLING, T; FIEBIG, H. H; KERPEL-FRONIUS, S et al.Investigational new drugs. 1996, Vol 14, Num 4, pp 371-378, issn 0167-6997Article

Effects of the microtubule-disturbing agents docetaxel (Taxotere®), vinblastine and vincristine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitroHANAUSKE, A.-R; DEPENBROCK, H; SHIRVANI, D et al.European journal of cancer. Part A. 1994, Vol 30, Num 11, pp 1688-1694Article

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitroBURRIS, H. A; HANAUSKE, A.-R; JOHNSON, R. K et al.Journal of the National Cancer Institute. 1992, Vol 84, Num 23, pp 1816-1820, issn 0027-8874Article

Alteration of EGF-receptor binding in human breast cancer cells by antineoplastic agentsHANAUSKE, A.-R; OSBORNE, C. K; CHAMNESS, G. C et al.European journal of cancer & clinical oncology. 1987, Vol 23, Num 5, pp 545-551, issn 0277-5379Article

Reproducibility of metabolic measurements in malignant tumors using FDG PETWEBER, W. A; ZIEGLER, S. I; THÖDTMANN, R et al.The Journal of nuclear medicine (1978). 1999, Vol 40, Num 11, pp 1771-1777, issn 0161-5505Article

Positron emission tomography in non-Hodgkin's lymphoma : Assessment of chemotherapy with fluorodeoxyglucoseRÖMER, W; HANAUSKE, A.-R; SCHWAIGER, M et al.Blood. 1998, Vol 91, Num 12, pp 4464-4471, issn 0006-4971Article

Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancerHANAUSKE, A.-R; KORFEL, A; ZWINGERS, T et al.Oncology. 1997, Vol 54, Num 5, pp 363-370, issn 0030-2414Article

Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 daysRASSMANN, I; SCHRÖDEL, H; SCHILLING, T et al.Investigational new drugs. 1996, Vol 14, Num 4, pp 379-386, issn 0167-6997Article

Assessment of biological activity of linear α-transforming growth factor and monospecific antibodies to α-transforming growth factor and linear α-transforming growth factorHANAUSKE, A.-R; BUCHOK, J. B; PARDUE, R. L et al.Cancer research (Baltimore). 1986, Vol 46, Num 11, pp 5567-5570, issn 0008-5472Article

Adenocarcinoma of unknown primary : retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning systemHANAUSKE, A.-R; CLARK, G. M; VON HOFF, D. D et al.Investigational new drugs. 1995, Vol 13, Num 1, pp 43-49, issn 0167-6997Article

Human colon cancer cell lines secrete αTGF ― like activityHANAUSKE, A. R; BUCHOK, J; SCHEITHAUER, W et al.British journal of cancer. 1987, Vol 55, Num 1, pp 57-59, issn 0007-0920Article

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatinTHÖDTMANN, R; DEPENBROCK, H; DUMEZ, H et al.Journal of clinical oncology. 1999, Vol 17, Num 10, pp 3009-3016, issn 0732-183XArticle

Gemcitabine and etoposide in small cell lung cancer : Phase I and II trialsRASSMANN, I; THÖDTMANN, R; DEPENBROCK, H et al.Seminars in oncology. 1997, Vol 24, Num 2, pp S7-75, issn 0093-7754, -S7-78, SUP7Article

Interleukin 1 modulates growth of human renal carcinoma cells in vitroKOCH, I; DEPENBROCK, H; DANHAUSER-RIEDL, S et al.British journal of cancer. 1995, Vol 71, Num 4, pp 794-800, issn 0007-0920Article

A new fibroblast growth stimulating activity from the human megakaryoblastic leukaemia cell line ELF-153 : in vitro and in vivo findingsHASSAN, H. T; HANAUSKE, A.-R; LUX, E et al.International journal of experimental pathology. 1995, Vol 76, Num 5, pp 361-367, issn 0959-9673Article

A new in vitro screening system for anticancer drugs for the treatment of non-small cell lung cancerHANAUSKE, U; HANAUSKE, A.-R; CLARK, G. M et al.Cancer drug delivery. 1989, Vol 5, Num 3, pp 97-111, issn 0732-9482Article

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211 : A study of the EORTC Early Clinical Studies Group (ECSG)SESSA, C; WANDERS, J; ROELVINK, M et al.Annals of oncology. 2000, Vol 11, Num 2, pp 207-210, issn 0923-7534Article

Essai de phase II cystémustine (60 mg/m²) dans les cancers bronchiques avancés ou métastatiques prétraités = Phase II trial with cystemustine (60 mg/m²) in advanced or metastatic pretreated lung carcinomaREBATTU, P; COUDERT, B; SCHNEIDER, M et al.Revue de pneumologie clinique (Paris). 2000, Vol 56, Num 3, pp 200-203, issn 0761-8417Article

Preclinical activity of 17β-[N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-l-alanyl]-5α-dihydrotestosterone (E91) against tumour colony forming units and haematopoietic progenitor cellsRANK, P; PETER, R; DEPENBROCK, H et al.European journal of cancer (1990). 1999, Vol 35, Num 6, pp 1009-1013, issn 0959-8049Article

Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumorsTHÖDTMANN, R; DEPENBROCK, H; BLATTER, J et al.Seminars in oncology. 1999, Vol 26, Num 2, pp 89-93, issn 0093-7754, SUP6Article